Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Multi-Center, Extension Study of V72P10 to Assess Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10.

NCT01148524 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01148524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01148524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Multi-Center, Extension Study of V72P10 to Assess Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10.
Lead sponsor
Novartis Vaccines
Phase
Phase 2/3
Overall status
Completed
Start date
August 31, 2010
Completion date
January 31, 2012
Enrollment
817 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal disease, meningococcal meningitis